Abstract
High rates of midterm failure of the Nellix EndoVascular Aneurysm Sealing (EVAS) system (Endologix, Irvine, Calif) led the UK Medicines and Health Regulatory Authority to recommend explantation of all devices. The study aim was to report outcomes of reintervention and explantation for failing EVAS.
Published Version (
Free)
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a callDisclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.
